Patent: 10,035,848
✉ Email this page to a colleague
Summary for Patent: 10,035,848
Title: | Antibody targeting cell surface deposited complement protein C3d and use thereof |
Abstract: | An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions. |
Inventor(s): | Wiestner; Adrian U. (Bethesda, MD), Skarzynski; Martin W. (North Bethesda, MD), Lindorfer; Margaret A. (Keswick, VA), Taylor; Ronald P. (Keswick, VA), Rader; Christoph (Jupiter, FL), Vire; Berengere (Le Cres, FR) |
Assignee: | The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) University of Virginia Patent Foundation (Charlottesville, VA) |
Application Number: | 15/110,577 |
Patent Claims: | see list of patent claims |
Details for Patent 10,035,848
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2034-01-08 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 10/26/2009 | ⤷ Try a Trial | 2034-01-08 |
Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 04/01/2011 | ⤷ Try a Trial | 2034-01-08 |
Novartis Pharmaceuticals Corporation | KESIMPTA | ofatumumab | Injection | 125326 | 08/20/2020 | ⤷ Try a Trial | 2034-01-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |